Hims & Hers Stock Just Plummeted 17%. Is the Stock a Buy Ahead of a Peptide Push?
Hims & Hers stock crashed 17% after issuing weak Q4 guidance, with revenue projections falling short of analyst expectations at $875-895 million versus expected $955.1 million. The company faces margin pressure from increased sales of lower-margin weight-loss drugs and international expansion. However, the upcoming launch of its Peptides+ category at month-end could provide significant growth opportunities, making the stock potentially attractive for long-term investors despite current headwinds.


